Reduce Patient Morbidity through patented devices for local delivery of proven antibiotics to the infection site
Reduce Provider's Liability of treatment failure, repeated procedures and impact to quality metrics
Reduce Total Cost of Care by shifting treatment away from more expensive, less effective treatment options
Periprosthetic Joint Infection (PJI) is devastating to patient health, frustrating to surgeons, and costly to healthcare systems. It represents a lifetime risk for any patient that has had joint replacement surgery and can occur in any replaced joint, including knees, hips, shoulders, etc.
The Current Standard of Care (SOC) for treatment is suboptimal. Multiple studies document high failure rates resulting in repeated surgeries and extended patient morbidity. Current treatment failure is primarily due to persistent bacterial biofilm, which is not eradicated by low concentration of antibiotics in the joint, a limitation with using current SOC administration.
By 2025, PJI (in total joint arthroplasty of hips and knees alone) will represent a total US economic burden of >$2.5B/yr with over 82,000 PJI cases projected each year.
PJI has a significant detrimental impact on the patient's quality of life due to the risk of implant replacement, the risk of amputation and prolonged exposure to antibiotics under suppression therapy.
Systemic (intravenous) drug delivery cannot achieve efficacious concentrations at the target anatomical location without risking drug side effects.
Targeted drug delivery is a proven clinical method in disease states where efficacy is defined by the concentration of drug in a specific anatomical location.
PJI is a tremendous burden on patients, providers and payors alike. PJI can occur in every total joint arthroplasty: TKA (knees), THA (hips), TSA (shoulders), etc.
Our Remote Implantable Drug Delivery System (RIDDS) technology provides targeted delivery using a simple subdermal implant and external controller.
The onboard reservoir holds sufficient antibiotic for >1 week of dosage, then refilled. The external controller operates the metered dosing to achieve optimal therapeutic concentration inside the joint.
By effectively treating biofilm, RIDDS can enable improved outccomes from less invasive treatment procedures, salvaging existing implants and thereby lowering costs and speeding patient recovery.